Upregulation of ATF3 expression inhibit the proliferation of human uterine serous carcinoma in vitro

Objects: To investigate the effects of ATF3 upregulation on the proliferation of human uterine serous carcinoma line SPEC-2 and its mechanism. Materials and Methods: Ampho-293 and HEK-293 Fast cells were used to prepare the virus. SPEC-2 cells were infected by polybrene. Western blot experiments were used to verify the success of transfection. The proliferation of cells was detected by MTT method. At different time points, the absorbance of the cells was detected at the wavelength of 490 nm at the enzyme linked immunosorbent assay. The expression of MTP53, ATF3, P21, and CyclinD1 in the cells was detected by Western blot. Results: In negative control and blank control groups, the expression of ATF3 cells was lower in SPEC-2 cells, while the expression of ATF3 protein in the transfection group was significantly higher (p < 0.05 ).The results of MTT showed that the growth rate of SPEC-2 cells was significantly lower than that in the control group. From the experimental results, it can be seen that the expression level of P21 increased, while the expression of MTP53 and CyclinD1 decreased significantly (p < 0.05). Conclusions: High expression of ATF3 in SPEC-2 cells could inhibit the proliferation in vitro. The expression of P21 was activated and the expression of mutant type P53, and CyclinD1 was inhibited which might be the molecular mechanism of inhibition of cell proliferation.

Uterine serous carcinoma; ATF3; SPEC-2; Proliferation.

[1] Seo K.W., Holt R., Jung Y.S., Rodriguez CO. Jr., Chen X, Rebhun R.B.: “Fluoroquinolone-mediated inhibition of cell growth,S-G2/M cell cycle arrest,and apoptosis in canine osteosarcoma cell lines”. PLoS One, 2012 ,7, e42960.

[2] Nagata M., Nakayama K., Terada Y., Hoshi S., Watanabe T.: “Cell cycle regulation and differentiation in the human podocyte lineage”. Am. J. Pathol.,1998, 153, 1511.

[3] Yang M., Zhong J., Zhao M., Wang J., Gu Y., Yuan X., et al.: “Overexpression of nuclear apoptosis-inducing factor 1 altered the proteomic profile of human gastric cancer cell MKN45 and induced cell cycle arrest at G1/S phase”. PLoS One, 2014, 9, e100216.

[4] Motokura T., Bloom T., Kim H.G., Jüppner H., Ruderman J.V., Kronenberg H.M., Arnold A.: “A novel cyclin encoded by a bcl1-linked candidate oncogen”. Nature, 1991, 350, 512.

[5] Finkielstein C.V., Chen L.G., Maller J.L.: “A role for G1/S cyclindependent protein kinases in the apoptotic response to ionizing radiation”. J. Biol. Chem., 2002, 277, 38476.

[6] Pedram A., Razandi M., Hu R.M., Levin E.R.: “Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction”. J. Biol. Chem.,1998, 273, 13966.

[7] Lim S., Kaldis P.: “Loss of Cdk2 and Cdk4 induces a switch from proliferation to differentiation in neural stem cells”. Stem Cells, 2012, 30, 1509.

[8] Du Z., Tong X., Ye X.: “Cyclin D1 promotes cell cycle progression through enhancing NDR1/2 kinase activity independent of cyclindependent kinase 4”. J. Biol. Chem., 2013, 288, 26678.

[9] Wu J., Lv Q., He J., Zhang H., Mei X., Cui K., et al.: “MicroRNA- 188 suppresses G1/S transition by targeting multiple cyclin/CDK complexes”. Cell Commun. Signal, 2014, 12, 66.

[10] Ohlson L.C., Koroxenidou L., Porsch-Hällström I.: “Mitoinhibitory effects of the tumor promoter 2-acetylaminofluorene in rat liver: loss of E2F-1 and E2F-3 expression and cdk 2 kinase activity in late G1”. J. Hepatol., 2004, 40, 957.

[11] Su C., Zhang C., Tecle A., Fu X., He J., Song J., et al.: “Tudor staphylococcal nuclease (Tudor-SN), a novel regulator facilitating G1/S phase transition, acting as a co-activator of E2F-1 in cell cycle regulation”. J.Biol.Chem., 2015, 290, 7208.

[12] Donati G., Montanaro L., Derenzini M.: “Ribosome biogenesis and control of cell proliferation: p53 is not alone”. Cancer Res., 2012, 72, 1602.

[13] Yu X., Blanden A.R., Narayanan S., Jayakumar L., Lubin D., Augeri D., et al.: “Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc metallochaperone based mechanism”. Oncotarget, 2014, 5, 8879.

[14] Cuddihy A.R., Jalali F., Coackley C., Bristow R.G.: “WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells”. Mol. Cancer Ther., 2008, 7, 980.

[15] Oren M., Rotter V.: “Mutant p53 gain-of-function in cancer”. Cold Spring Harb. Perspect. Biol., 2010, 2, a001107.

[16] Cadwell C., Zambetti G.P.: “The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth”. Gene, 2001, 277, 15.

[17] Roemer K.: “Mutant p53: gain-of-function oncoproteins and wildtype p53 inactivators”. Biol. Chem., 1999, 380, 879.

[18] Zhou G., Wang J., Zhao M., Xie T.X., Tanaka N., Sano D., et al.: “Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation”. Mol. Cell, 2014, 54, 960.

[19] Hai T., Hartman M.G.: “The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis”. Gene, 2001, 273, 1.

[20] Koren L., Elhanani O., Kehat I., Hai T., Aronheim A.: “Adult cardiac expression of the activating transcription factor 3, ATF3, promotes ventricular hypertrophy”. PloS One, 2013, 8, e68396.

[21] Jang M.K., Son Y., Jung M.H.: “ATF3 plays a role in adipocyte hypoxia- mediated mitochondria dysfunction in obesity”. Biochem.Biophys. Res.Commun., 2013, 431, 421.

[22] Hackl C., Lang S.A., Moser C., Mori A., Fichtner-Feigl S., Hellerbrand C., et al.: “Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heatshock protein 90 (Hsp90) inhibition”. BMC Cancer, 2010, 10, 668.

[23] Wang Z., Xu D., Ding H.F., Kim J., Zhang J., Hai T., Yan C.: “Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model”. Oncogene, 2015, 34, 4975.

[24] Xie J.J., Xie Y.M., Chen B., Pan F., Guo J.C., Zhao Q., Shen J.H., et al. :“ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma”. Oncotarget, 2014, 5, 8569.

[25] Wang H., Mo P., Ren S., Yan C.:“Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6”. J. Biol.Chem., 2010, 285, 13201.

[26] Wang C.M., Brennan V.C., Gutierrez N.M., Wang X., Wang L., Yang W.H.: “SUMOylation of ATF3 alters its transcriptional activity on regulation of TP53 gene”. J. Cell Biochem., 2013, 114, 589.

[27] Wei S., Wang H., Lu C., Malmut S., Zhang J., Ren S., et al.: “The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins”. J. Biol. Chem., 2014, 289, 8947.